- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01374620
Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel (PAL-ANGI2)
Phase I Study : Dose Escalation of Intravenous Weekly Paclitaxel in Association With Metronomic Administration of Cyclophosphamide
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59000
- Centre OSCAR LAMBRET
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with cancer histologically proved
- No other therapeutic proposal after discussion in multidisciplinary consultation
- Radiological evidence of the evolving nature of the disease
- Measurable disease with at least one measurable lesion according to the criteria RECIST 1.1
- At least 28 days since prior treatment(systemic treatment or major surgery)
- Patient who have recovered from any previous toxicity
- Man or woman de ≥ 18 years and ≤ 65 years
- Performance Status (ECOG) ≤ 2 within 7 days before inclusion
- Polynuclear neutrophils ≥ 1500/mm3, platelets ≥ 100 000/mm3, Hemoglobin ≥ 9 g/dl
- Serum Albumin ≥ 36 g/l and lymphocytes ≥ 700/mm3
- Total bilirubin and SGPT/ALT and SGOT/AST ≤ 3 ULN(≤ 5 ULN if liver metastases)
- Creatinine in normal ranges and Creatinine clairance > 60 ml/min (Cockroft formulae)
- Central venous access
- Negative pregnancy test for women who may be pregnant within 7 days before inclusion
- Effective contraceptive during the treatment period and up to 6 months after the end of treatment (for patients of both sexes during their reproductive and child-bearing age and their partners)
- Patient covered by government health insurance
- Informed consent signed by the patient before any specific study procedure
Exclusion Criteria:
- Prior treatment by Paclitaxel
- Oral treatment impossible
- Known dysphagia, malabsorption or maldigestion
- Pre-existing neuropathy clinically symptomatic
- Known leptomeningeal brain metastases
- Known allergy to Cremophor, to Paclitaxel or one of its excipients (especially polyoxyethylene castor oil), to Cyclophosphamide or one of its excipients (lactose, sucrose)
- Active and uncontrolled infection
- Acute urinary tract infection, pre-existing hemorrhagic cystitis
- Diabetes insipidus
- History or progressive psychiatric illness
- Persons under guardianship or detainees
- Unable for medical follow-up (geographic, social or mental reasons)
- Pregnant, or likely to be or breastfeeding women
- Absence of effective contraception for the duration of treatment and 6 months after completion of therapy (for patients of both sexes in childbearing or reproductive age and their partners)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paclitaxel Dose escalation
A standard dose escalation strategy will be used including 3 to 6 patients at each dose level (Paclitaxel dose escalation + fixed dose of cyclophosphamide) + blood collection |
Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose. The Paclitaxel dose (mg/infusion) levels are as follows:
Other Names:
D1 to D28: 50 mg x 2/day/cycle 1 cycle = 28 days
Other Names:
At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
|
Experimental: Cohort extension
An additional 10 patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose + blood collection |
D1 to D28: 50 mg x 2/day/cycle 1 cycle = 28 days
Other Names:
At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the iv paclitaxel maximum tolerated dose and recommended dose in association with a fixed dose of oral cyclophosphamide
Time Frame: 28 days = cycle 1
|
A DLT is defined below: Hematological toxicity:
Non-hematological toxicity: Any grade 3 or 4 toxicity related to study treatment, with the exception of fatigue and alopecia |
28 days = cycle 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Description of the nature of adverse events
Time Frame: During the study treatment, an expected average of 2 months
|
According to the NCI-CTCAE scale v4.0
|
During the study treatment, an expected average of 2 months
|
Evaluation of objective response after 2 cycles
Time Frame: After 2 cycles = 2 months
|
Objective response (complete response, partial response and stable disease) according to RECIST 1.1 criteria
|
After 2 cycles = 2 months
|
Estimation of the free-progression median time
Time Frame: Until disease progression
|
Time between the inclusion and the disease progression (clinical or radiological)
|
Until disease progression
|
Calculation of the Growth Modulation Index (GMI)
Time Frame: Until disease progression
|
Time to progression on study treatment and time to progression on prior treatment
|
Until disease progression
|
Evaluation of the correlation between clinical response and biological parameters
Time Frame: Day 1, 8, 15, 21 of cycle 1 and cycle 2
|
Biological parameters related to angiogenesis
|
Day 1, 8, 15, 21 of cycle 1 and cycle 2
|
Description of the severity of adverse events
Time Frame: During the study treatment, an expected average of 2 months
|
According to the NCI-CTCAE scale v4.0
|
During the study treatment, an expected average of 2 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Cyclophosphamide
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- PAL-ANGI2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Paclitaxel dose escalation
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
Weill Medical College of Cornell UniversityActive, not recruiting
-
Cliniques universitaires Saint-Luc- Université...UnknownHead and Neck CancerBelgium
-
National Cancer Institute, EgyptRecruitingHead and Neck CancerEgypt
-
University Hospital OlomoucUniversity Hospital Ostrava; Masaryk Memorial Cancer InstituteRecruitingHypoxia | Head and Neck Cancer | Dose Escalation | FMISOCzechia
-
Royal North Shore HospitalRecruitingPalliative RadiotherapyAustralia
-
Hinova Pharmaceuticals Inc.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Istituto Clinico HumanitasRecruitingNon Small Cell Lung Cancer | Lung MetastasesItaly
-
Emory UniversityCompletedBrain Metastasis | NeoplasmUnited States
-
Hinova Pharmaceuticals Aus Pty LtdCompletedMetastatic Castration-resistant Prostate CancerAustralia